Dose-Response Relationship of DNA and Recombinant Fowlpox Virus Prime-Boost HIV Vaccines

Implications For Future Trials

Robert De Rose1,†
Mark T. Sullivan1,2,†
C. Jane Dale1
Anthony D. Kelleher2
Sean Emery2
David A. Cooper2
Ian A. Ramshaw3
David B. Boyle4
Stephen J. Kent1,*

1Department of Microbiology and Immunology; University of Melbourne; Parkville, Victoria Australia
2National Centre in HIV Epidemiology and Clinical Research; University of New South Wales; Sydney, New South Wales Australia
3John Curtin School of Medical Research; Australian National University; Canberra Australian Capital Territory Australia
4CSIRO Livestock Industries; Australian Animal Health Laboratory; Geelong, Victoria Australia
†These authors contributed equally to this work.

Received 03/10/06; Accepted 05/10/06

This manuscript has been published online, prior to printing for Human Vaccines, Volume 2, Issue 3. Definitive page numbers have not been assigned. The current citation is: Human Vaccines 2006; 2(3): http://www.landesbioscience.com/journals/vaccines/abstract.php?id=2940

We have conducted five separate trials of DNA and rFPV prime-boost HIV vaccines expressing multiple HIV-1 or SHIV antigens at various doses in 25 pigtail and 16 cynomolgous macaques and an initial clinical trial in 18 humans (Fig. 1).3,9-11 All vaccines were administered intramuscularly without adjuvants, with 2 or 3 priming DNA vaccines at 3–4 weekly intervals followed by 1 or 2 rFPV boosters at 4-week intervals. Eight macaques received HIV-1 vaccines at the lowest dose of 0.15 mg DNA/7.5 x 10^6pfu of rFPV. Twenty-two received 1 mg DNA/5 x 10^7pfu rFPV doses of HIV or SHIV vaccines (16 HIV-1 vaccines and 6 SHIV vaccines), 8 received 2 mg DNA/10^8pfu rFPV of HIV-1 vaccines and 3 received HIV-1 vaccines at the highest dose of 4.5 mg DNA/2 x 10^8pfu rFPV. In each trial, the ratio of DNA and rFPV doses was maintained within a narrow range (4.4-5.0 x 10^7pfu of rFPV/mg of DNA vaccine).

Immunological responses were observed in almost all macaques at the three highest doses of DNA/rFPV studied (1 mg/10^7pfu, 2 mg/10^8pfu and 4.5 mg/2 x 10^8pfu, respectively) with positive responses of 95%–100% by IFNγ ELISpot, 79%–100% by enzyme immunoassay (EIA) and 100% by western blot (WB) (Fig. 1A). T-cell responses were confirmed by ICS for the 1 mg/10^7pfu and 4.5 mg/2 x 10^8pfu doses.3,9,10 However, the lowest dose studied (0.15 mg/10^7pfu) was poorly immunogenic, eliciting responses in only 2/8 animals by ELISpot and 1/8 animals by WB and EIA. This suggests that the minimal effective dose of the combination of vaccines is between 0.15 mg/7.5 x 10^6pfu and 1 mg/5 x 10^7pfu in macaques.

An initial clinical trial at the 1 mg/5 x 10^7pfu dose was recently performed in 18 human subjects.12 Although the vaccines were well tolerated at this dose, T-cell responses by IFNγ ELISpot were only observed in 4/18 and antibody responses by EIA and WB in 1/18 subjects. Given the similarity in vaccine construction and manufacture, mode of administration...
and efficacy measures, the difference between the human and nonhuman primate data raises the question of the adequacy of the dose used in humans. Other novel HIV vaccines candidates have also failed to reliably elicit T-cell immunity in clinical trials despite promising results in preclinical trials.\(^5\)\(^7\) Guiding principles to normalize doses of novel T-cell-based vaccines from nonhuman primates to humans are likely to be helpful.

For many drugs, dose calculations for extrapolating differences in size and weight from preclinical to clinical trials are made using estimated body surface area (BSA).\(^13\)\(^14\) BSA is a good predictor of malarial antigens and is normalised for BSA, doses of DNA vaccine greater than 3.9 mg/m\(^2\) of BSA (1 mg/5 x 10\(^7\)pfu) were immunogenic in macaques (Fig. 1B). The poorly immunogenic dose of 0.8 mg/m\(^2\) BSA (0.15 mg/7.5 x 10\(^6\)pfu) in macaques was similar to the poorly immunogenic dose in the clinical trial (0.7 mg/m\(^2\), 1 mg/5 x 10\(^7\)pfu). On the basis of BSA, there was an approximately 6-fold difference in the DNA and rFPV vaccine doses used in the human study compared with the minimal immunogenic dose in macaques. We hypothesise that dose is a factor and that taking into account BSA-based calculations could potentially guide investigators to more relevant doses of novel T-cell-based HIV vaccines for humans.

The impact that vaccine dose can have on immunogenicity of DNA prime/viral vector boost vaccine modalities has been highlighted in two recent clinical trials. DNA and MVA vaccines encoding malarial antigens were administered at various doses and dosing regimes in order to optimize vaccine performance.\(^16\) Higher doses (2 mg DNA vaccine/1.5 x 10\(^8\)pfu MVA) were found to be more immunogenic than low doses in humans (1 mg/3 x 10\(^7\)pfu). Lower doses of SIV-based DNA/MVA vaccines were previously demonstrated to induce strong T cell immunogenicity in rhesus macaques.\(^6\)\(^7\)\(^19\) Recent human DNA vaccine trials conducted at the NIH Vaccine Research Center also suggest that 4–8 mg of DNA vaccine may be required to efficiently stimulate T-cell immunity.\(^20\) This is in line with our predictions that up to 6-fold increases in the dose of DNA and rFPV vaccines we studied in the clinical trial may be required to efficiently stimulate T-cell immunity (Fig. 1B). The human population studied may also need to be taken into account since many Asian populations will have significantly lower BSA levels and, in some instances responses to drug therapies, compared to Caucasian populations.\(^21\)

As further animal and human data are published on novel HIV vaccine vectors, it will be possible to evaluate whether our observations on DNA/rFPV vectors are confirmed and can be generalized to other vector-based vaccines. Conference reports suggest that adeno-associated virus vectors have also demonstrated suboptimal immunogenicity in humans despite promising macaque immunogenicity reported with SIV vectors.\(^22\)\(^23\) Alternatively, adenovirus serotype 5 vectors have been immunogenic in both rhesus macaques using SIV vectors and, at conference presentations, in humans with HIV-1 vectors, although the dose that is required for optimal immunogenicity is high (often ≥10\(^9\) virus particles).\(^24\)\(^25\) Larger doses of Canarypoxvirus vectors (without DNA priming) did not improve T cell immunogenicity in a human trial and were associated with unacceptable reactogenicity.\(^26\) For DNA and poxvirus vectors, scale up of doses much beyond 5 mg and 5 x 10\(^8\) pfu respectively is likely to be expensive, require larger volumes of injection or multiple injections, and associated with more reactogenicity.

Alternate biologic explanations of the differences between humans and nonhuman primates in immunogenicity of DNA/ poxvirus vectors are also possible and should be further explored. It is possible that differences in entry and expression of vaccine vectors

---

**Figure 1.** Dose Response of DNA prime/rFPV boost vaccines. a) T-cell immunogenicity was assessed by IFNy ELISpot assay to overlapping HIV or SIV Gag peptide pools or inactivated HIV-1 particles 1-5 weeks after the final rFPV boost and plotted as a proportion of positive responders \(> 50 \text{sfc}/10^6\) PBMC. Humoral immunity was measured by EIA \(\bullet\) and increased p24 band density in western blot \(\square\). b) Body surface area-normalized comparison of vaccine exposure. Four vaccine doses from macaque trials, one clinical trial and a proposed clinical trial, expressed as BSA. Dose for DNA vaccine only is shown on the vertical axis - the rFPV vaccine dose is closely scaled to the DNA vaccine dose in all trials [4.4 - 5.0 x 10^7 pfu/mg DNA vaccine]. BSA (m\(^2\)): Human = ([Height(cm) x Weight(kg)]/3600)^1/2, Monkeys = (K\(_m\) [11.8 for monkeys] x Weight(kg)^0.67)/100.
within target APC populations exist between macaques and humans but are not yet well understood. This may be a particular problem for avian viral vectors such as rFPV that undergo an abortive replication cycle in mammalian cells. The stage at which replication of avian poxvirus vectors are blocked may however, be different between various mammalian species and influence immunogenicity.\textsuperscript{,27,28}

An additional limitation of comparing some macaque and human HIV vaccines studies is that few other groups have reported the immunogenicity of the same HIV-1 vectors in both macaques and humans. Differences in the immunodominance T cell epitopes between SIV and HIV-1 will exist. Some macaque vaccine studies have primarily selected animals with particular MHC alleles that present immunodominant SIV epitopes such as the CM9 SIV Gag epitopes in rhesus macaques.\textsuperscript{,6,17,19,29} This will skew the immunogenicity towards a positive response in SIV studies in comparison to studying more outbred populations with HIV-1 vaccines.

Extensive dose-ranging studies of novel T-cell-based HIV vaccines in clinical trials involve considerable time, effort and resources. The dose of novel vaccines chosen has important implications for regulatory requirements and practicality and cost of scaling up the required doses for human use. More predictive measures of vaccine dose from preclinical models, such as using BSA-based calculations, could assist streamlining studies of effective doses.

References